CN119235874A - 用于前列腺癌的联合疗法 - Google Patents

用于前列腺癌的联合疗法 Download PDF

Info

Publication number
CN119235874A
CN119235874A CN202411589875.XA CN202411589875A CN119235874A CN 119235874 A CN119235874 A CN 119235874A CN 202411589875 A CN202411589875 A CN 202411589875A CN 119235874 A CN119235874 A CN 119235874A
Authority
CN
China
Prior art keywords
nilaparib
day
patient
administered
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411589875.XA
Other languages
English (en)
Chinese (zh)
Inventor
M·K·于
L·A·斯尼德尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62067858&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN119235874(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN119235874A publication Critical patent/CN119235874A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
CN202411589875.XA 2017-04-13 2018-04-09 用于前列腺癌的联合疗法 Pending CN119235874A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762485164P 2017-04-13 2017-04-13
US62/485164 2017-04-13
PCT/US2018/026661 WO2018191141A1 (en) 2017-04-13 2018-04-09 Combination therapy for prostate cancer
CN201880039365.1A CN110753545A (zh) 2017-04-13 2018-04-09 用于前列腺癌的联合疗法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880039365.1A Division CN110753545A (zh) 2017-04-13 2018-04-09 用于前列腺癌的联合疗法

Publications (1)

Publication Number Publication Date
CN119235874A true CN119235874A (zh) 2025-01-03

Family

ID=62067858

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880039365.1A Pending CN110753545A (zh) 2017-04-13 2018-04-09 用于前列腺癌的联合疗法
CN202411589875.XA Pending CN119235874A (zh) 2017-04-13 2018-04-09 用于前列腺癌的联合疗法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201880039365.1A Pending CN110753545A (zh) 2017-04-13 2018-04-09 用于前列腺癌的联合疗法

Country Status (33)

Country Link
US (4) US20180296574A1 (enExample)
EP (3) EP4176879A1 (enExample)
JP (3) JP7141408B2 (enExample)
KR (1) KR20190134718A (enExample)
CN (2) CN110753545A (enExample)
AU (2) AU2018251594A1 (enExample)
CA (1) CA3059562A1 (enExample)
CL (1) CL2019002871A1 (enExample)
CO (1) CO2019011591A2 (enExample)
CR (1) CR20190467A (enExample)
DK (1) DK3609497T3 (enExample)
DO (1) DOP2019000264A (enExample)
EA (1) EA201992430A1 (enExample)
ES (1) ES2931052T3 (enExample)
HR (1) HRP20221327T1 (enExample)
HU (1) HUE060460T2 (enExample)
IL (2) IL269879B2 (enExample)
JO (1) JOP20190244A1 (enExample)
LT (1) LT3609497T (enExample)
MA (1) MA48728B1 (enExample)
MD (1) MD3609497T2 (enExample)
MX (2) MX2019012296A (enExample)
MY (1) MY209010A (enExample)
NI (1) NI201900105A (enExample)
PE (1) PE20200444A1 (enExample)
PH (1) PH12019502317A1 (enExample)
PL (1) PL3609497T3 (enExample)
PT (1) PT3609497T (enExample)
RS (1) RS63832B1 (enExample)
SG (1) SG11201909552VA (enExample)
SM (1) SMT202200467T1 (enExample)
UA (1) UA129514C2 (enExample)
WO (1) WO2018191141A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS66574B1 (sr) 2016-07-29 2025-03-31 Janssen Pharmaceutica Nv Niraparib za upotrebu u postupku lečenja raka prostate
WO2020139339A1 (en) * 2018-12-27 2020-07-02 Constellation Pharmaceuticals, Inc. Ezh2 and androgen receptor signaling inhibitors as tools for targeting prostate cancer
JP7442328B2 (ja) * 2020-02-03 2024-03-04 株式会社三共 遊技機
CN113546037B (zh) * 2020-04-20 2024-12-27 鲁南制药集团股份有限公司 一种醋酸阿比特龙栓剂及其制备方法
MX2022014003A (es) * 2020-05-08 2022-11-30 Janssen Pharmaceutica Nv Tratamientos del cancer de prostata con combinaciones de acetato de abiraterona y niraparib.
CN114306236B (zh) * 2021-12-15 2022-10-21 湖南慧泽生物医药科技有限公司 用于负载醋酸阿比特龙的自微乳体系及组合物和应用
EP4197541B1 (en) 2021-12-15 2024-07-24 Hunan Huize Biopharma S&T Co., Ltd Abiraterone acetate-containing composition and application thereof
KR20240170958A (ko) * 2022-04-07 2024-12-05 아스트라제네카 아베 암 치료를 위한 병용 요법
WO2024203348A1 (ja) * 2023-03-31 2024-10-03 ソニーグループ株式会社 腫瘍の解析方法、腫瘍の解析システム、及び腫瘍の解析データ生成方法
WO2025027138A1 (en) * 2023-08-02 2025-02-06 Janssen Pharmaceutica Nv Combination of niraparib and abiraterone for use in the treatment of metastatic castration-resistant prostate cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080051380A1 (en) * 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
NZ597830A (en) * 2006-08-25 2013-02-22 Cougar Biotechnology Inc Methods and compositions for treating cancer comprising abiraterone acetate and prednisone
RS51780B (sr) 2007-01-10 2011-12-31 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.R.L. Indazoli supstituisani amidom kao inhibitori poli(adp-riboza)polimeraze (parp)
NZ586675A (en) 2008-01-08 2012-04-27 Merck Sharp & Dohme Pharmaceutically acceptable salts of 2-{ 4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide
WO2012009475A1 (en) * 2010-07-14 2012-01-19 Oregon Health & Science University Methods of treating cancer with inhibition of lysine-specific demethylase 1
US9314473B2 (en) * 2011-02-03 2016-04-19 Pop Test Oncology Limited Liability Company System and method for diagnosis and treatment
WO2014089324A1 (en) * 2012-12-07 2014-06-12 Calitor Sciences, Llc Substituted cyclic compounds and methods of use

Also Published As

Publication number Publication date
MA48728A (fr) 2020-04-08
AU2018251594A1 (en) 2019-10-24
CO2019011591A2 (es) 2020-02-28
EP4176879A1 (en) 2023-05-10
PT3609497T (pt) 2023-01-23
MX2019012296A (es) 2019-11-28
JP7141408B2 (ja) 2022-09-22
NI201900105A (es) 2020-03-11
SMT202200467T1 (it) 2023-01-13
US20180296574A1 (en) 2018-10-18
EP4176878A1 (en) 2023-05-10
RS63832B1 (sr) 2023-01-31
PL3609497T3 (pl) 2023-01-23
JP7407880B2 (ja) 2024-01-04
JP2022141881A (ja) 2022-09-29
PH12019502317A1 (en) 2020-07-06
IL269879B1 (en) 2025-06-01
JP2020516646A (ja) 2020-06-11
IL320452A (en) 2025-06-01
MY209010A (en) 2025-06-16
LT3609497T (lt) 2022-12-12
KR20190134718A (ko) 2019-12-04
SG11201909552VA (en) 2019-11-28
MD3609497T2 (ro) 2023-03-31
JP2024023344A (ja) 2024-02-21
WO2018191141A1 (en) 2018-10-18
HRP20221327T1 (hr) 2023-03-17
BR112019021466A2 (pt) 2020-05-12
IL269879A (enExample) 2019-11-28
IL269879B2 (en) 2025-10-01
PE20200444A1 (es) 2020-02-28
US20220175801A1 (en) 2022-06-09
US20240245710A1 (en) 2024-07-25
CL2019002871A1 (es) 2019-12-27
AU2024202346A1 (en) 2024-05-02
UA129514C2 (uk) 2025-05-21
DOP2019000264A (es) 2020-07-15
JOP20190244A1 (ar) 2019-10-13
ES2931052T3 (es) 2022-12-23
MX2023009569A (es) 2023-08-22
CA3059562A1 (en) 2018-10-18
CN110753545A (zh) 2020-02-04
US20240398837A1 (en) 2024-12-05
MA48728B1 (fr) 2022-10-31
EP3609497A1 (en) 2020-02-19
EA201992430A1 (ru) 2020-02-28
HUE060460T2 (hu) 2023-03-28
DK3609497T3 (da) 2022-10-31
EP3609497B1 (en) 2022-10-12
CR20190467A (es) 2020-03-09

Similar Documents

Publication Publication Date Title
US20240398837A1 (en) Combination Therapy For Prostate Cancer
TW202302112A (zh) 索托拉西布給藥方案
KR20210105388A (ko) 암 치료에서 사용하기 위한 raf 저해제와 cdk4/6 저해제를 이용하는 병용요법
EP4301356A1 (en) Treatment of breast cancer with amcenestrant and palbociclib
WO2023049363A1 (en) Sotorasib and afatinib for treating cancer comprising a kras g12c mutation
HK40092155A (en) Combination therapy for prostate cancer
EA044835B1 (ru) Комбинированная терапия рака предстательной железы
KR20150003786A (ko) Pi3k 저해제 및 mek 저해제를 이용한 암 치료 방법
US20250170146A1 (en) Niraparib and abiraterone acetate plus prednisone to improve clinical outcomes in patients with metastatic castration-resistant prostate cancer and hrr alterations
BR112019021466B1 (pt) Composição compreendendo niraparibe, acetato de abiraterona, e prednisona, bem como uso dos referidos compostos
Dębska-Szmich et al. Clinical use of cyclin-dependent kinase (CDK) 4/6 inhibitors in patients with breast cancer—literature review
TW202404599A (zh) 使用經取代之嘧啶-4(3h)-酮及納武單抗(nivolumab)之組合療法
WO2025027138A1 (en) Combination of niraparib and abiraterone for use in the treatment of metastatic castration-resistant prostate cancer
EP4665725A2 (en) Methods of treating solid tumors with mitogen activated protein kinase (mapk) pathway alterations
CN117580572A (zh) 用安森司坦和帕博西尼治疗乳腺癌

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination